^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA WITH MYD88 AND CXCR4 MUTATIONS

Published date:
05/12/2021
Excerpt:
This study examines the safety and efficacy of mavorixafor in combination with ibrutinib in patients with WM with MYD88 and CXCR4 mutations….Six out of 7 patients showed decrease in IgM after 1 cycle. Four patients were treated for ≥3 cycles; all had decrease in serum IgM, with 2 achieving a ≥50% decrease from baseline consistent with partial response after 3 cycles (median decrease, 51.0%; range, 4.4%–84.5%).
Trial ID: